Pier Capital LLC Sells 37,511 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Pier Capital LLC lowered its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 27.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 96,863 shares of the company’s stock after selling 37,511 shares during the period. Pier Capital LLC owned about 0.21% of Omnicell worth $4,312,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Smartleaf Asset Management LLC boosted its holdings in shares of Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock worth $35,000 after buying an additional 273 shares during the last quarter. Van ECK Associates Corp boosted its stake in Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after acquiring an additional 315 shares during the last quarter. First Horizon Advisors Inc. grew its position in shares of Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after acquiring an additional 355 shares during the period. KBC Group NV grew its position in shares of Omnicell by 60.8% during the 4th quarter. KBC Group NV now owns 2,057 shares of the company’s stock valued at $92,000 after acquiring an additional 778 shares during the period. Finally, AlphaQuest LLC increased its stake in shares of Omnicell by 307.8% during the 4th quarter. AlphaQuest LLC now owns 3,576 shares of the company’s stock worth $159,000 after purchasing an additional 2,699 shares during the last quarter. Institutional investors own 97.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on OMCL. Bank of America dropped their price objective on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research note on Monday, January 6th. JPMorgan Chase & Co. dropped their price target on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, March 20th. Wells Fargo & Company reduced their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. StockNews.com cut Omnicell from a “buy” rating to a “hold” rating in a research report on Monday. Finally, Benchmark reaffirmed a “buy” rating and set a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $51.00.

Omnicell Price Performance

Shares of Omnicell stock opened at $35.14 on Tuesday. Omnicell, Inc. has a 12 month low of $25.12 and a 12 month high of $55.75. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The business’s 50-day moving average price is $39.63 and its 200-day moving average price is $42.83. The firm has a market capitalization of $1.64 billion, a PE ratio of 130.15, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Sell-side analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.